Tag Archive for: psilocybin

Video: Karin’s depression treatment at the OVID Practice Berlin (SWR1 – “What’s good about … drugs?”)

Pharmacologically based long-term therapies are often the treatment of choice for depression. Augmented psychotherapy, which uses mind-altering substances such as ketamine, is a new approach to helping depressed people. The altered states of consciousness induced in this way are then therapeutically integrated This treatment method, which is still relatively new in Germany, is the focus of Dr. med. Andrea Jungaberle and her colleagues in their clinic in Berlin Friedrichshain. Esanum visited the interdisciplinary team and informed us about the innovative procedure.
The esanum physician network has made a video report about the newly opened OVID Clinic Berlin. In it, Andrea Jungaberle, MD, Sergio Pérez and members of the team of therapists present the concept for psychedelic-augmented psychotherapy. Augmented means “amplified, expanded, intensified”.

Special Issue of Pharmacopsychiatry on Psychedelics in Psychiatry 2021 – the characteristics of disruptive treatments

Special Issue of Pharmacopsychiatry on Psychedelics in Psychiatry 2021 – Gerhard Gründer and Henrik Jungaberle on the difference of disruptive treatments


Henrik Jungaberle

Cover Pharmacopsychiatry Psychedelics 2021.jpg


A special issue of Pharmacopsychiatry

„Psychedelics in Psychiatry 2021“

The July 2021 special issue of Psychopharmacology is dedicated to the renaissance of psychedelics in psychiatry that has occurred during the past couple of years. “Psychedelics in Psychiatry 2021” contains four interesting review articles on different aspects of its historic development and current research as treatment in mood disorders and its effects in psychotherapy.
Together with Gerhard Gründer Henrik Jungaberle has co-authored a paper on “The potential role of psychedelic drugs in mental health care of the future”.

Prof. Dr. Gerhard Gründer describes the scope of the special issue in his editoral:

“It is important to be aware of the historical roots of our current medical practices. This is particularly true of the use of psychedelics for medical purposes. Nichols and Walter in their thoughtful review provide an overview of the historical basis on which all current psychedelic treatment research is based [5]. Treatment with a psychedelic is not just the application of a pill. Rather, it must always be embedded in psychotherapeutic support. The scope and nature of this psychotherapeutic program are the subjects of intense research, the current status of which is presented in the overview by Nayak and Johnson [6]. What is the mechanism of action of psychedelics? The entire spectrum of psychological and biological processes that are triggered by psychedelics is the subject of the review by Mertens and Preller [7]. They discuss the current state of research using the example of 2 possible future therapeutic indications, affective and substance use disorders. Finally, psychedelic therapy not only requires a new infrastructure in which it is carried out but also must be integrated into the existing system and differentiated from the recreational use of these substances. Many social, political, and cultural questions are affected by this enculturation. The challenges of how psychedelics could be implemented in a future mental health care system are discussed by Gründer and Jungaberle [8].”

July, 15th, 2021






Conference: INSIGHT 2021 – an invitation to Berlin. Psychedelic research, therapy and drug development in Berlin

At INSIGHT 2021, scientists and therapists, pharmaceutical industry and anthropology, philosophers, and chemists will come together to determine the potential place of LSD, psilocybin, DMT, MDMA, and other psychedelic substances in the treatment of mental disorders. In addition, we will discuss the use of non-pharmacological methods to alter and cultivate states of consciousness and all that it takes to build such unusual states of consciousness a legitimate and safe place in society.

Writing the histories of psychedelic research: Wirtschaftswoche on German LSD-Researcher Hanscarl Leuner

German journalist Marlene Halser on the LSD-researcher Hanscarl Leuner
“Psychedelic mushrooms are in demand on the stock market – this man paved the way for them” (Wirtschaftswoche)

For almost 30 years, Hanscarl Leuner treated people with LSD and psilocybin at the University Hospital in Göttingen. Substances in which highly valued start-ups are currently investing – while the German researcher has been relegated to the sidelines of society.”
… and a free link to “The History of Psychedelics in Psychiatry”

Video: Psychedelic therapy serious – The physician portal esanum reports about the OVID Clinic Berlin

Pharmacologically based long-term therapies are often the treatment of choice for depression. Augmented psychotherapy, which uses mind-altering substances such as ketamine, is a new approach to helping depressed people. The altered states of consciousness induced in this way are then therapeutically integrated This treatment method, which is still relatively new in Germany, is the focus of Dr. med. Andrea Jungaberle and her colleagues in their clinic in Berlin Friedrichshain. Esanum visited the interdisciplinary team and informed us about the innovative procedure.
The esanum physician network has made a video report about the newly opened OVID Clinic Berlin. In it, Andrea Jungaberle, MD, Sergio Pérez and members of the team of therapists present the concept for psychedelic-augmented psychotherapy. Augmented means “amplified, expanded, intensified”.

Podcast: Henrik in conversation with Darek Dwanda on values and programs of the MIND Foundation

Berlin’s MIND Foundation is one of Europe’s largest psychedelic therapy organizations with global aspirations. MIND has a range of amazing programs for therapists, academics, and anyone else interested in new psychedelic therapies. In this episode we discuss a range of issues including European psychedelic landscape, ethics of Psychedelic-Assisted Therapies, cultural issues, issues of growth, and many other issues related to healing with psychedelics.

Gert Scobel discusses drugs as medicine on 3SAT – with Franz Vollenweider, Thomas Metzinger und Magaly Tornay

Gert Scobel discusses new therapies with hallucinogenic drugs with historian Magaly Tornay, psychiatrist Franz Vollenweider, and philosopher and neuroethicist Thomas Metzinger.

Essay: Ecstasy – Expedition to an Unknown Land in Spektrum der Wissenschaft Spezial: Rituale. Was unser Leben zusammenhält

Ecstasy derives from the Greek and means something like “being outside oneself” and “stepping out,” which means a temporary shifting of the personal coordinate system. This holds the chance of a new perspective, but also the danger of losing oneself. The general characteristics of altered states of waking consciousness include changes in self-, world-, and time-perception, especially emotionalization, intensification of visual and auditory experience, bodily perceptions, and intensified experience of meaning. As a rule, in such states the experience shifts away from the ego-like controlled, to the intoxicating being carried in a stream of fragmentary inner events. It is precisely this passive “being carried” that can have a seductive and “habituating” quality for unstable people.

Conference: Intoxication as Risk and Challenge – New Ways of Substance Misuse Prevention

In 2007, Dr. Henrik Jungaberle prepared the later drug education program REBOUND with the Karlsruhe conference “Intoxication and Risk – New Ways of Substance Misuse Prevention”.